Most studies investigated the prognostic ability of AFP among HCC patients receiving specific therapies on a retrospective nature, and several important confounding factors such as tumor burden, severity of cirrhosis, vascular invasion and performance status were not comprehensively adjusted [6,7]. This evidence concerns the gene AFP and neoplasm.